1. Company said in its PR today:
"Given the serious nature of anti-TNF resistant RA, we believe that MPC-300-IV is well-positioned to be developed as a regenerative advanced therapy to target this major unmet medical need."
In about just over three months, the Phase 2 RA trial will be completed. Look for MSB pushing for accelerated approval after that, without the need for a Phase 3.
2. With such great results, Mesoblast continues to put three major pharma companies on notice.
Mesoblast's RA treatment bettered (in the initial 12 week result timeframe itself):
a) Humira, the highest grossing prescription drug on the planet, used primarily for RA
Humira is made by AbbVie, whose revenues are $23 billion USD, $14 billion of which are from Humira. AbbVie has a market cap of $110 billion USD
b) It also bettered Baricitinib, which recently finished Phase 3. Baricitinib is made by a partnership between Eli Lilly and Incyte, whose combined market cap is $105 billion.
Baricitinib is a prescription drug to treat RA, which is touted to be better than Humira.
So Mesoblast RA treatment > Baricitinib > Humira
But wait!
This. Is. The. Best. Part:
A SINGLE MSB injection resulted in durable response through 9 months.
One and done for 9 months at a time? Seriously.
Compare that to daily doses with serious side effects from taking Humira and Baricitnib.
Let the fun begin.
@Rappa: Sorry couldn't resist your fave colors man.
- Forums
- ASX - By Stock
- MSB
- Two GREAT takeaways
Two GREAT takeaways
-
- There are more pages in this discussion • 34 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.14 |
Change
0.045(4.13%) |
Mkt cap ! $1.284B |
Open | High | Low | Value | Volume |
$1.10 | $1.14 | $1.08 | $5.397M | 4.861M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
21 | 136601 | $1.13 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.14 | 236340 | 22 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
20 | 136364 | 1.130 |
14 | 59494 | 1.125 |
15 | 298774 | 1.120 |
9 | 86457 | 1.115 |
6 | 29314 | 1.110 |
Price($) | Vol. | No. |
---|---|---|
1.135 | 40707 | 5 |
1.140 | 209510 | 18 |
1.145 | 239980 | 11 |
1.150 | 373854 | 17 |
1.155 | 47000 | 3 |
Last trade - 14.33pm 18/06/2024 (20 minute delay) ? |
|
|||||
Last
$1.13 |
  |
Change
0.045 ( 4.06 %) |
|||
Open | High | Low | Volume | ||
$1.10 | $1.14 | $1.08 | 1075535 | ||
Last updated 14.53pm 18/06/2024 ? |
Featured News
MSB (ASX) Chart |
The Watchlist
SS1
SUN SILVER LIMITED
Gerard O'Donovan, Executive Director
Gerard O'Donovan
Executive Director
SPONSORED BY The Market Online